Satellos Tackles Duchenne ‘As Stem Cell People Solving a Stem Cell Problem’ — Click image below to read more! || #Scrip | Start your free trial today: https://t.co/tdKxRhffXH

Satellos will participate in two investor events this December: a company presentation at the @Piper_Sandler Healthcare Conference and a panel discussion at the @Oppenheimer Movers in Rare Disease Summit. We look forward to sharing our progress and the momentum behind our work in

We were proud to bring together representatives from all 25 sites across eight countries for the “Basecamp” Investigator Meeting in Milan, Italy, last week, supporting preparation for our Phase 2 study of SAT-3247 in children with #Duchenne. With 67 attendees from our site teams,

In this part of the @RadiusResearch interview, Satellos Co-Founder and CEO Frank Gleeson highlights both the urgency and the opportunity in bringing a truly new standard of care to boys with #Duchenne and explains why now is the time for change. 🎥 Clip below

$MSCL.TO $MSCLF

Satellos is pleased to share new research in @NatureComms from collaborators at @OttawaHospital, led by our co-founder and Chief Discovery Officer, Dr. Michael Rudnicki. The findings show Duchenne begins as a muscle stem cell disease and provide further support for AAK1 as a

Families like Charlie’s remind us what it means to live with #Duchenne — the strength it takes, the hope they hold, and the future they deserve. Read Charlie’s story: https://t.co/YD9NHnj3jv #MuscleRegeneration #SatellosStories $MSCLF $MSCL (Sound on 🎧)

In a recent @CheckRare feature, Satellos CMO Dr. Wildon Farwell discusses the science behind SAT-3247 and how restoring the #muscleregeneration process could offer a new therapeutic approach for people living with #Duchenne muscular dystrophy. Watch the interview:

We appreciate the opportunity to speak with @RadiusResearch about Satellos’ clinical progress as we work to advance a potential first-in-class treatment for degenerative muscle diseases. 🎬 Watch the full interview below with CEO Frank Gleeson, CMO Dr. Wildon Farwell, and CFO

🧬 Advancing Muscle Repair & Regeneration @SatellosBio (TSX: $MSCL | OTCQB: $MSCLF) CEO Frank Gleeson, CMO Dr. Wildon Farwell, and CFO Elizabeth Williams discuss key clinical updates, milestones, and what’s next in their mission to treat #degenerativemusculardiseases. 🎬 Watch

Dosing has begun in a long-term extension study testing Satellos Bioscience’s experimental oral therapy SAT-3247 in men with DMD. https://t.co/z8otMiK8pw #musculardystrophynews #musculardystrophy #musculardystrophycommunity #livingwithMD

The Satellos leadership team will participate in healthcare investor conferences next month in Boston and New York. We look forward to the conversations ahead. https://t.co/q0R5VEPvAL #Duchenne #MuscleRegeneration $MSCL $MSCLF

#SatellosStories: When Marissa Lenger moved from preclinical research into clinical data management, she found what had been missing: the connection to people. “With preclinical research being such an early step in the process of drug development, you rarely witness the

Momentum continues as the first patient is dosed in our long-term follow-up study! #Duchenne #MuscleRegeneration $MSCL.TO $MSCLF

#ICYMI, the Satellos team had a fantastic week at the @WorldMuscleSoc Congress (#WMS2025)! From poster sessions to great conversations, it was inspiring to connect with scientists, clinicians, and advocates advancing research across the muscle disease community. Here’s a quick

Satellos says oral drug shows early signs of efficacy in Duchenne study

It’s always meaningful to see our work come together on a global stage. Today, at the @WorldMuscleSoc Congress, @SatellosBio shared an update on SAT-3247. Grateful to everyone who helped make it happen. #WMS2025 #Duchenne #MuscleRegeneration $MSCLF $MSCL.TO

Hello from Vienna! The Satellos team is on site at the @WorldMuscleSoc 2025 Congress, ready to connect, learn, and share insights on restoring #muscleregeneration in #Duchenne. Be sure to stop by Booth #12 to meet our team and learn more about our work. Don’t miss our

The Satellos team is looking forward to participating in the 30th Annual Congress of the @WorldMuscleSoc in Vienna, Oct. 7–11. Don’t miss our scientific poster presentations, including a late-breaking poster on our Phase 1a/b study. Details here: https://t.co/TaW3br4fqD Be sure

Satellos Bioscience is planning a Phase 2 trial in the U.S. to test SAT-3247 in children with Duchenne who are able to walk. https://t.co/LfdyaNodVW #musculardystrophynews #musculardystrophy #musculardystrophycommunity #livingwithMD